| Vertex to Participate in Upcoming Investor Conferences |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions. |
businesswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft |
The Investment Committee give you their top names to watch for the second half. |
youtube.com |
2025-05-09 17:38:58 |
Czytaj oryginał (ang.) |
| Vertex to Present at 20th Annual Needham Technology, Media, & Consumer Conference |
KING OF PRUSSIA, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the 20th Annual Needham Technology, Media, & Consumer Conference. |
globenewswire.com |
2025-05-08 22:45:00 |
Czytaj oryginał (ang.) |
| Vertex, Inc. (VERX) Q1 2025 Earnings Call Transcript |
Vertex, Inc. (NASDAQ:VERX ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Joe Crivelli - Vice President of Investor Relations David DeStefano - President and Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham & Company, LLC Christopher Quintero - Morgan Stanley Adam Hotchkiss - Goldman Sachs George Cruz - Citigroup Inc. Jake Roberge - William Blair & Company Kyle Aberasturi - BMO Capital Markets Alexander Sklar - Raymond James Financial, Inc. William Jellison - D.A. Davidson & Co. Rob Oliver - Robert W. |
seekingalpha.com |
2025-05-08 03:41:03 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 14:36:21 |
Czytaj oryginał (ang.) |
| Vertex (VERX) Q1 Earnings and Revenues Top Estimates |
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago. |
zacks.com |
2025-05-07 13:25:50 |
Czytaj oryginał (ang.) |
| Vertex Announces First Quarter 2025 Financial Results |
KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-07 11:05:00 |
Czytaj oryginał (ang.) |
| Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip |
Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. |
fool.com |
2025-05-07 08:49:00 |
Czytaj oryginał (ang.) |
| Vertex On Track To Significantly Improve Revenue And Earnings By 2030 |
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets. |
seekingalpha.com |
2025-05-07 02:12:20 |
Czytaj oryginał (ang.) |
| Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? |
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings. |
benzinga.com |
2025-05-06 20:28:44 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. |
The company discloses narrower-than-expected access to its new painkiller. |
barrons.com |
2025-05-06 16:31:00 |
Czytaj oryginał (ang.) |
| Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More |
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell. |
investopedia.com |
2025-05-06 16:06:09 |
Czytaj oryginał (ang.) |
| Why Vertex Pharmaceuticals Stock Is Sinking Today |
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. |
fool.com |
2025-05-06 14:36:08 |
Czytaj oryginał (ang.) |
| Rising Costs Weigh on Vertex Q1 Earnings |
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report. |
fool.com |
2025-05-06 13:11:46 |
Czytaj oryginał (ang.) |
| Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade) |
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward. |
seekingalpha.com |
2025-05-06 12:04:32 |
Czytaj oryginał (ang.) |
| Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug |
Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. |
reuters.com |
2025-05-05 20:18:15 |
Czytaj oryginał (ang.) |
| Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum? |
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues. |
benzinga.com |
2025-05-05 18:59:30 |
Czytaj oryginał (ang.) |
| Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group |
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it! |
youtube.com |
2025-04-30 17:38:29 |
Czytaj oryginał (ang.) |
| Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:05:50 |
Czytaj oryginał (ang.) |
| Vertex Announces Strategic Investment in AI Tax Compliance Startup Kintsugi |
KING OF PRUSSIA, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, today announced it has completed a strategic investment in Kintsugi, a San Francisco-based, AI-native startup focused on automating sales tax compliance for small and mid-size businesses (SMBs). Terms of the agreement include a $15 million minority investment representing a 10 percent ownership interest, as well as IP sharing and a commercial arrangement. Additionally, Vertex will join the Kintsugi Board of Directors. |
globenewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG |
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. |
youtube.com |
2025-02-27 15:53:30 |
Czytaj oryginał (ang.) |
| Vertex, Inc. (VERX) Q4 2024 Earnings Call Transcript |
Vertex, Inc. (NASDAQ:VERX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Joe Crivelli – Vice President of Investor Relations David DeStefano – President and Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Rob Oliver – Baird Chris Quintero – Morgan Stanley Joshua Reilly – Needham Samad Samana – Jefferies Steve Enders – Citi Daniel Jester – BMO Capital Markets Jacob Roberge – William Blair Alex Sklar – Raymond James Patrick Walravens – Citizens William Jellison – D.A. Davidson Adam Hotchkiss – Goldman Sachs Operator Good morning and welcome to the Vertex Incorporated Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-27 14:29:29 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Vertex (VERX) Q4 Earnings |
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-27 12:36:18 |
Czytaj oryginał (ang.) |
| Vertex (VERX) Tops Q4 Earnings and Revenue Estimates |
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago. |
zacks.com |
2025-02-27 11:25:33 |
Czytaj oryginał (ang.) |
| Vertex Announces Fourth Quarter and Full Year 2024 Financial Results |
KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-27 09:05:00 |
Czytaj oryginał (ang.) |
| Vertex to Report Q4 Earnings: What's in Store for the Stock? |
VERX's fourth-quarter 2024 performance is likely to have benefited from the growing adoption of cloud-based tax automation solutions. |
zacks.com |
2025-02-24 13:56:09 |
Czytaj oryginał (ang.) |
| Countdown to Vertex (VERX) Q4 Earnings: Wall Street Forecasts for Key Metrics |
Get a deeper insight into the potential performance of Vertex (VERX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-02-24 12:22:09 |
Czytaj oryginał (ang.) |
| Vertex to Participate in Upcoming March Investor Conferences |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice Pres. |
businesswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing |
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. |
fool.com |
2025-02-14 06:35:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX |
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-13 09:30:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX |
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-12 09:30:00 |
Czytaj oryginał (ang.) |
| Calls of the Day: Charles Schwab, Vertex Pharma and Transocean |
The Investment Committee debate the latest Calls of the Day. |
youtube.com |
2025-02-11 16:21:14 |
Czytaj oryginał (ang.) |
| Vertex: Strong Sales, Stronger Pipeline |
Here's our initial take on Vertex Pharmaceuticals' (VRTX 0.14%) fourth-quarter financial report. |
fool.com |
2025-02-11 11:15:00 |
Czytaj oryginał (ang.) |
| Vertex's Revenue Surges but EPS Slips |
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion. |
fool.com |
2025-02-10 19:56:16 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals' Revenue Forecast Tops Expectations |
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations. |
investopedia.com |
2025-02-10 18:40:40 |
Czytaj oryginał (ang.) |
| Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand |
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions from a newly approved non-opioid painkiller. |
reuters.com |
2025-02-10 18:14:06 |
Czytaj oryginał (ang.) |
| Vertex Reports Fourth Quarter and Full Year 2024 Financial Results |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its full year 2025 financial guidance. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch. |
businesswire.com |
2025-02-10 18:01:00 |
Czytaj oryginał (ang.) |
| Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings |
Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025. |
benzinga.com |
2025-02-10 09:24:04 |
Czytaj oryginał (ang.) |
| Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise |
The Investment Committee give you their top stocks to watch for the second half. |
youtube.com |
2025-02-05 15:30:14 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses. |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accessnewswire.com |
2025-02-05 09:25:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2025-01-02 09:30:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested |
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic fibrosis (CF) drug market, including recent FDA approval for Alyftrek, ensures strong revenue and market expansion. The company's pipeline diversification, targeting diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, promises long-term growth. |
seekingalpha.com |
2024-12-31 11:02:47 |
Czytaj oryginał (ang.) |
| S&P 500 Winners Fortinet, Boston Scientific Lead 5 Stocks Near Buy Points |
S&P 500 components Fortinet and Boston Scientific are among five stocks to watch near buy points as 2024 comes to a close. The post S&P 500 Winners Fortinet, Boston Scientific Lead 5 Stocks Near Buy Points appeared first on Investor's Business Daily. |
investors.com |
2024-12-28 10:00:49 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip |
Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. |
fool.com |
2024-12-26 10:30:00 |
Czytaj oryginał (ang.) |
| Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Vertex (VERX) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2024-12-25 15:46:08 |
Czytaj oryginał (ang.) |
| Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on. |
businesswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek |
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta. |
zacks.com |
2024-12-23 16:46:11 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst |
Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint. |
benzinga.com |
2024-12-23 13:13:58 |
Czytaj oryginał (ang.) |
| Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? |
Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas. |
fool.com |
2024-12-22 06:30:00 |
Czytaj oryginał (ang.) |
| Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock |
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday. The post Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock appeared first on Investor's Business Daily. |
investors.com |
2024-12-20 20:16:07 |
Czytaj oryginał (ang.) |
| US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment |
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in the market for cystic fibrosis. |
reuters.com |
2024-12-20 18:01:36 |
Czytaj oryginał (ang.) |
| Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See. |
businesswire.com |
2024-12-20 17:46:00 |
Czytaj oryginał (ang.) |
| Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants |
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In ad. |
businesswire.com |
2024-12-20 17:35:00 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX |
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. |
accesswire.com |
2024-12-20 17:00:00 |
Czytaj oryginał (ang.) |
| Cramer's Mad Dash: Vertex Pharmaceuticals |
CNBC's Jim Cramer delivers his daily Mad Dash. |
youtube.com |
2024-12-20 12:12:22 |
Czytaj oryginał (ang.) |
| Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? |
Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study. The post Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? |
investors.com |
2024-12-20 10:00:15 |
Czytaj oryginał (ang.) |
| Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot |
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks. |
youtube.com |
2024-12-19 16:11:22 |
Czytaj oryginał (ang.) |
| Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? |
On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. |
benzinga.com |
2024-12-19 15:06:32 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years |
Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study. |
schaeffersresearch.com |
2024-12-19 13:23:03 |
Czytaj oryginał (ang.) |
| Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results |
Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain. |
investopedia.com |
2024-12-19 12:31:29 |
Czytaj oryginał (ang.) |